Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients

References

• Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science132, 1497 (1960).
   Web of Science ®Google Scholar
• Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature243(5405), 290–293 (1973).
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med.355(23), 2408–2417 (2006).
   PubMed Web of Science ®Google Scholar
• Deininger M, O’Brien SG, Guilhot F et al. International Randomized Study of Interferon vs STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Presented at: 51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Kantarjian H, Talpaz M, O’Brien S et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood103(8), 2873–2878 (2004).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Talpaz M, O’Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood101(2), 473–475 (2003).
   PubMed Web of Science ®Google Scholar
• Cortes J, Giles F, O’Brien S et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood102(1), 83–86 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Larson RA, Guilhot F et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer115(3), 551–560 (2009).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Baccarani M, Guilhot F et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J. Clin. Oncol.28(3), 424–430 (2010).
   PubMed Web of Science ®Google Scholar
• Hehlmann R, Jung-Munkwitz S, Lauseker M et al. Superior CMR-rates with tolerability-adapted imatinib 800 mg vs 400 mg vs 400 mg + IFN in CML: the randomized German CML-study IV. Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Castagnetti F, Palandri F, Amabile M et al. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a Phase 2 trial of the GIMEMA CML Working Party. Blood113(15), 3428–3434 (2009).
   PubMed Web of Science ®Google Scholar
• Baccarani M, Rosti G, Castagnetti F et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood113(19), 4497–4504 (2009).
   PubMed Web of Science ®Google Scholar
• Preudhomme C, Guilhot J, Nicolini FE et al. Imatinib plus peginterferon α-2a in chronic myeloid leukemia. N. Engl. J. Med.363(26), 2511–2521 (2010).
   PubMed Web of Science ®Google Scholar
• Hughes TP, Branford S, White DL et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood112(10), 3965–3973 (2008).
   PubMed Web of Science ®Google Scholar
• Palandri F, Castagnetti F, Iacobucci I et al. The combination of interferon-α with imatinib in early chronic phase chronic myeloid leukemia patients induces a significant improvement of the molecular responses in the first two years of treatment: results from three studies from the GIMEMA CML working party. Presented at: 51st Annual meeting of American Society of Hematology. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Cortes J, Borthakur G, O’Brien S et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP). Blood114(22), 338 (2009).
   PubMedGoogle Scholar
• Kantarjian H, Shah NP, Hochhaus A et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med.362(24), 2260–2270 (2010).
   PubMed Web of Science ®Google Scholar
• Muller MC, Cortes JE, Kim DW et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR–ABL mutations. Blood114(24), 4944–4953 (2009).
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr–Abl. Cancer Cell7(2), 129–141 (2005).
   PubMed Web of Science ®Google Scholar
• Rosti G, Castagnetti F, Gugliotta G et al. excellent outcomes at 3 years with nilotinib 800 mg daily in early chronic phase, Ph+ chronic myeloid leukemia (CML): results of a Phase 2 GIMEMA CML WP clinical trial. Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Rosti G, Palandri F, Castagnetti F et al. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood114(24), 4933–4938 (2009).
   PubMed Web of Science ®Google Scholar
• Cortes JE, Jones D, O’Brien S et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J. Clin. Oncol.28(3), 392–397 (2010).
   PubMed Web of Science ®Google Scholar
• Hughes T, Hochhaus A, Saglio G et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.362(24), 2251–2259 (2010).
   PubMed Web of Science ®Google Scholar
• Sokal JE, Cox EB, Baccarani M et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood63(4), 789–799 (1984).
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon α. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J. Natl Cancer Inst.90(11), 850–858 (1998).
   PubMed Web of Science ®Google Scholar
• White D, Saunders V, Lyons AB et al. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood106(7), 2520–2526 (2005).
   PubMed Web of Science ®Google Scholar
• White D, Saunders V, Grigg A et al. Measurement of in vivo BCR–ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. J. Clin. Oncol.25(28), 4445–4451 (2007).
   PubMed Web of Science ®Google Scholar
• Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood104(12), 3739–3745 (2004).
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood108(2), 697–704 (2006).
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood110(12), 4064–4072 (2007).
   PubMed Web of Science ®Google Scholar
• White DL, Dang P, Engler J et al. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J. Clin. Oncol.28(16), 2761–2767 (2010).
   PubMed Web of Science ®Google Scholar
• Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood106(3), 1133–1134 (2005).
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin. Pharmacol. Ther.83(2), 258–264 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang WW, Cortes JE, Yao H et al. Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance. J. Clin. Oncol.27(22), 3642–3649 (2009).
   PubMed Web of Science ®Google Scholar
• Hiwase DK, Saunders V, Hewett D et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin. Cancer Res.14(12), 3881–3888 (2008).
   PubMed Web of Science ®Google Scholar
• Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, Clark RE. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood112(8), 3348–3354 (2008).
   PubMed Web of Science ®Google Scholar
• Hegedus C, Ozvegy-Laczka C, Apati A et al. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br. J. Pharmacol.158(4), 1153–1164 (2009).
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol.27(35), 6041–6051 (2009).
   PubMed Web of Science ®Google Scholar
• Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR–ABL. Leukemia20(4), 664–670 (2006).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Parkinson I et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR–ABL kinase domain mutations. Blood104(9), 2926–2932 (2004).
   PubMed Web of Science ®Google Scholar
• Marin D, Milojkovic D, Olavarria E et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood112(12), 4437–4444 (2008).
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood108(6), 1809–1820 (2006).
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J. Clin. Oncol.26(20), 3358–3363 (2008).
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Kantarjian H, O’Brien S et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer115(16), 3709–3718 (2009).
   PubMed Web of Science ®Google Scholar
• Hughes TP, Hochhaus A, Branford S et al. Reduction of BCR–ABL transcript levels at 6, 12, and 18 months (mo) correlates with long-term outcomes on imatinib (IM) at 72 mo: an analysis from the international randomized study of interferon versus STI571 (IRIS) in patients (pts) with chronic phase chronic myeloid leukemia (CML-CP). Presented at: 50th Annual Meeting of American Society of Hematology. San Francisco, CA, USA, 6–9 December 2008.
   Google Scholar
• Hughes TP, Hochhaus A, Branford S et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood116(19), 3758–3765 (2010).
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood109(8), 3496–3499 (2007).
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood111(8), 4022–4028 (2008).
   PubMed Web of Science ®Google Scholar
• Noens L, van Lierde MA, De Bock R et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood113(22), 5401–5411 (2009).
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J. Clin. Oncol.28(14), 2381–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D et al. Frequency and clinical significance of BCR–ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia20(10), 1767–1773 (2006).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. Detection of BCR–ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood102(1), 276–283 (2003).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin AS et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia16(11), 2190–2196 (2002).
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Amabile M et al. Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to imatinib. Clin Chem,50(7), 1205–1213 (2004).
   PubMed Web of Science ®Google Scholar
• Deininger MW, McGreevey L, Willis S, Bainbridge TM, Druker BJ, Heinrich MC. Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia18(4), 864–871 (2004).
   PubMed Web of Science ®Google Scholar
• Ernst T, Erben P, Muller MC et al. Dynamics of BCR–ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica93(2), 186–192 (2008).
   PubMed Web of Science ®Google Scholar
• Branford S, Goh H-G, Izzo B et al. A review of mutation analysis in the tops trial of standard dose versus high dose IM in CML suggests that refinements to the ELN recommendations for mutation screening may be appropriate. ASH Annual Meeting Abstracts116(21), 889 (2010).
   Google Scholar
• Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW. Determining the rise in BCR–ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood114(13), 2598–2605 (2009).
   PubMed Web of Science ®Google Scholar
• Tsaur G, Ivanova A, Popov A et al. Evaluation of BCR–ABL/ABL ratio increase that corresponds to BCR–ABL mutation in chronic myeloid leukemia patients treated by imatinib. ASH Annual Meeting Abstracts116(21), 3422 (2010).
   Google Scholar
• Wang L, Knight K, Lucas C, Clark RE. The role of serial BCR–ABL transcript monitoring in predicting the emergence of BCR–ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica91(2), 235–239 (2006).
   PubMed Web of Science ®Google Scholar
• Shah NP. Loss of response to imatinib: mechanisms and management. Hematology Am. Soc. Hematol. Educ. Program2005(1), 183–187 (2005).
   Google Scholar
• Hochhaus A, Druker B, Sawyers C et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment. Blood111(3), 1039–1043 (2008).
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a Phase II study. Blood99(10), 3530–3539 (2002).
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase 2 study. Blood99(6), 1928–1937 (2002).
   PubMed Web of Science ®Google Scholar
• Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science293(5531), 876–880 (2001).
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood99(9), 3472–3475 (2002).
   PubMed Web of Science ®Google Scholar
• Cowan-Jacob SW, Guez V, Fendrich G et al. Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem.4(3), 285–299 (2004).
   PubMed Web of Science ®Google Scholar
• Shah NP, Nicoll JM, Nagar B et al. Multiple BCR–ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell2(2), 117–125 (2002).
   PubMed Web of Science ®Google Scholar
• Hughes T, Saglio G, Branford S et al. Impact of baseline BCR–ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J. Clin. Oncol.27(25), 4204–4210 (2009).
   PubMed Web of Science ®Google Scholar
• Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol.8(11), 1018–1029 (2007).
   PubMed Web of Science ®Google Scholar
• Guilhot F, Apperley J, Kim DW et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood109(10), 4143–4150 (2007).
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin. Cancer Res.12(24), 7374–7379 (2006).
   PubMed Web of Science ®Google Scholar
• Cortes J, Rousselot P, Kim DW et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood109(8), 3207–3213 (2007).
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Pavlova A et al. Kinase domain mutations of BCR–ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood110(2), 727–734 (2007).
   PubMed Web of Science ®Google Scholar
• Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR–ABL mutation status really matter? Blood114(27), 5426–5435 (2009).
   PubMed Web of Science ®Google Scholar
• von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR–ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet359(9305), 487–491 (2002).
   Google Scholar
• Hofmann WK, Jones LC, Lemp NA et al. Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR–ABL gene mutation. Blood99(5), 1860–1862 (2002).
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J et al. BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood101(2), 690–698 (2003).
   PubMed Web of Science ®Google Scholar
• Hiwase DK, White DL, Powell JA et al. Blocking cytokine signaling along with intense Bcr–Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia24(4), 771–778 (2010).
   PubMed Web of Science ®Google Scholar
• Wang Y, Cai D, Brendel C et al. Adaptive secretion of granulocyte–macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Blood109(5), 2147–2155 (2007).
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of α1 acid glycoprotein in the in vivo resistance of human BCR–ABL+ leukemic cells to the abl inhibitor STI571. J. Natl Cancer Inst.92(20), 1641–1650 (2000).
   PubMed Web of Science ®Google Scholar
• Mahon FX, Belloc F, Lagarde V et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood101(6), 2368–2373 (2003).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Hamerschlak N et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase 2 trial. Blood109(12), 5143–5150 (2007).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Pasquini R, Levy V et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized Phase 2 study (START-R). Cancer115(18), 4136–4147 (2009).
   PubMed Web of Science ®Google Scholar
• Mauro M, Baccarani M, Cervantes F et al. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J. Clin. Oncol.26(20 Suppl.), 7009 (2008).
   Google Scholar
• Hochhaus A, Baccarani M, Deininger M et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia22(6), 1200–1206 (2008).
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian HM, Baccarani M et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood109(6), 2303–2309 (2007).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian HM, Jones D et al. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR–ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood112(13), 4839–4842 (2008).
   PubMed Web of Science ®Google Scholar
• Soverini S, Colarossi S, Gnani A et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR–ABL kinase domain. Haematologica92(3), 401–404 (2007).
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med.354(24), 2542–2551 (2006).
   PubMed Web of Science ®Google Scholar
• Cortes J, Jabbour E, Kantarjian H et al. Dynamics of BCR–ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood110(12), 4005–4011 (2007).
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr–Abl+ neoplastic cells. Cancer Res.66(23), 11314–11322 (2006).
   PubMed Web of Science ®Google Scholar
• Bruemmendorf T, Cervantes F, Kim D, Chandy M, Fischer T, Hochhaus A. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. Presented at: 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May–3 June 2008.
   Google Scholar
• Milojkovic D, Nicholson E, Apperley JF et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica95(2), 224–231 (2010).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, O’Brien S et al. Predictive factors for outcome and response in patients treated with second generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase post imatinib failure. Blood117(6), 1822–1827 (2010).
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N et al. Nilotinib (formerly AMN107), a highly selective BCR–ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood110(10), 3540–3546 (2007).
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood112(1), 53–55 (2008).
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Morisset S, Hochhaus A et al. The presence of the BCR–ABL T315I mutation in chronic phase chronic myelogenous leukemia resistant to tyrosine kinase inhibitors profoundly compromises overall survival and progression free survival. Preliminary results of a matched pair analysis. Blood116(21), 3410 (2010).
   Google Scholar
• Cortes J, Talpaz M, Bixby D et al. A Phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: emerging safety and clinical response findings. Blood116(21), 210 (2010).
   PubMedGoogle Scholar
• Cortes-Franco J, Dombret H, Schafhausen P et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Presented at: 51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Cortes J, Roboz GJ, Kantarjian HM et al. A Phase I dose escalation study of KW-2449, an oral multi-kinase inhibitor against FLT3, Abl, FGFR1 and Aurora in patients with relapsed/refractory AML, ALL and MDS or resistant/intolerant CML. Presented at: 50th Annual Meeting of American Society of Hematology. San Francisco, CA, USA, 6–9 December 2008.
   Google Scholar
• Cortes JE, Wetzler M, Lipton J et al. Subcutaneous omacetaxine (OM) treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients following multiple tyrosine kinase inhibitor (TKI) failure. Presented at: 52nd Annual Meeting of American Society of Hematology. Orlando, FL, USA, 4–7 December 2010.
   Google Scholar
• Branford S, Kim D-W, Soverini S et al. Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP). Presented at: 51st Annual Meeting of American Society of Hematology. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Tam CS, Kantarjian H, Garcia-Manero G et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood112(3), 516–518 (2008).
   PubMed Web of Science ®Google Scholar
• Hughes TP, Kaeda J, Branford S et al. Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med.349(15), 1423–1432 (2003).
   PubMed Web of Science ®Google Scholar